Spruce Biosciences (SPRB) Competitors $0.06 0.00 (-4.13%) As of 03:08 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SPRB vs. IMNN, NERV, BCTX, BGXX, AFMD, ABP, LSB, TLPH, PHXM, and ATHAShould you be buying Spruce Biosciences stock or one of its competitors? The main competitors of Spruce Biosciences include Imunon (IMNN), Minerva Neurosciences (NERV), BriaCell Therapeutics (BCTX), Bright Green (BGXX), Affimed (AFMD), Abpro (ABP), Lakeshore Biopharma (LSB), Talphera (TLPH), PHAXIAM Therapeutics (PHXM), and Athira Pharma (ATHA). These companies are all part of the "pharmaceutical products" industry. Spruce Biosciences vs. Imunon Minerva Neurosciences BriaCell Therapeutics Bright Green Affimed Abpro Lakeshore Biopharma Talphera PHAXIAM Therapeutics Athira Pharma Imunon (NASDAQ:IMNN) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability. Do analysts prefer IMNN or SPRB? Imunon presently has a consensus target price of $15.50, indicating a potential upside of 3,590.48%. Spruce Biosciences has a consensus target price of $2.17, indicating a potential upside of 3,487.20%. Given Imunon's stronger consensus rating and higher possible upside, analysts plainly believe Imunon is more favorable than Spruce Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Imunon 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.75Spruce Biosciences 0 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media prefer IMNN or SPRB? In the previous week, Imunon had 13 more articles in the media than Spruce Biosciences. MarketBeat recorded 13 mentions for Imunon and 0 mentions for Spruce Biosciences. Imunon's average media sentiment score of 0.31 beat Spruce Biosciences' score of 0.00 indicating that Imunon is being referred to more favorably in the media. Company Overall Sentiment Imunon Neutral Spruce Biosciences Neutral Which has higher valuation and earnings, IMNN or SPRB? Imunon has higher earnings, but lower revenue than Spruce Biosciences. Imunon is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImunon$500K14.74-$19.51M-$1.36-0.31Spruce Biosciences$4.91M0.52-$47.92M-$1.32-0.05 Is IMNN or SPRB more profitable? Imunon has a net margin of 0.00% compared to Spruce Biosciences' net margin of -555.23%. Spruce Biosciences' return on equity of -62.10% beat Imunon's return on equity.Company Net Margins Return on Equity Return on Assets ImunonN/A -230.05% -128.98% Spruce Biosciences -555.23%-62.10%-47.49% Which has more risk & volatility, IMNN or SPRB? Imunon has a beta of 1.75, suggesting that its stock price is 75% more volatile than the S&P 500. Comparatively, Spruce Biosciences has a beta of 2.49, suggesting that its stock price is 149% more volatile than the S&P 500. Does the MarketBeat Community favor IMNN or SPRB? Spruce Biosciences received 14 more outperform votes than Imunon when rated by MarketBeat users. However, 92.59% of users gave Imunon an outperform vote while only 54.17% of users gave Spruce Biosciences an outperform vote. CompanyUnderperformOutperformImunonOutperform Votes2592.59% Underperform Votes27.41%Spruce BiosciencesOutperform Votes3954.17% Underperform Votes3345.83% Do institutionals and insiders believe in IMNN or SPRB? 4.5% of Imunon shares are held by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are held by institutional investors. 5.0% of Imunon shares are held by insiders. Comparatively, 9.1% of Spruce Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. SummaryImunon beats Spruce Biosciences on 10 of the 19 factors compared between the two stocks. Get Spruce Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SPRB vs. The Competition Export to ExcelMetricSpruce BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.55M$6.49B$5.33B$8.43BDividend YieldN/A2.64%5.21%4.11%P/E Ratio-0.069.1226.8519.75Price / Sales0.52256.15388.74118.67Price / CashN/A65.8538.2534.62Price / Book0.036.436.764.50Net Income-$47.92M$144.21M$3.23B$248.32M7 Day PerformanceN/A2.25%1.71%0.48%1 Month PerformanceN/A4.39%11.16%13.08%1 Year PerformanceN/A-2.71%17.17%7.36% Spruce Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SPRBSpruce Biosciences1.8879 of 5 stars$0.06-4.1%$2.17+3,487.2%-91.8%$2.55M$4.91M-0.0620Gap DownIMNNImunon1.5723 of 5 stars$0.82+2.0%$21.50+2,535.1%-72.3%$11.93M$500,000.00-0.4330News CoverageAnalyst ForecastGap UpNERVMinerva Neurosciences2.9216 of 5 stars$1.66+2.9%$5.00+201.9%-41.1%$11.58MN/A-3.769News CoverageAnalyst ForecastGap UpBCTXBriaCell Therapeutics1.3184 of 5 stars$3.12+0.3%$32.00+925.6%-84.5%$11.57MN/A-0.238BGXXBright GreenN/AN/AN/AN/A$11.47MN/A-1.002News CoverageGap DownAFMDAffimed4.381 of 5 stars$0.69+1.2%$13.50+1,848.1%-96.5%$11.16M$877,000.000.00200Analyst ForecastAnalyst RevisionGap DownABPAbproN/A$0.21+4.9%$4.00+1,806.6%N/A$10.96M$183,000.000.0015Earnings ReportGap DownHigh Trading VolumeLSBLakeshore Biopharma0.7155 of 5 stars$1.16+1.8%N/AN/A$10.80M$672.27M0.00773High Trading VolumeTLPHTalphera2.7511 of 5 stars$0.52-3.4%$5.00+858.8%-51.8%$10.69M$281,000.00-0.7619PHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58M$32.66M0.0049ATHAAthira Pharma1.6969 of 5 stars$0.27+6.2%$13.83+5,023.5%-89.4%$10.54MN/A-0.0940Gap Down Related Companies and Tools Related Companies Imunon Competitors Minerva Neurosciences Competitors BriaCell Therapeutics Competitors Bright Green Competitors Affimed Competitors Abpro Competitors Lakeshore Biopharma Competitors Talphera Competitors PHAXIAM Therapeutics Competitors Athira Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SPRB) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spruce Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spruce Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SPRB Stock Free SPRB Stock Alerts